DAWNZERA (AUTOINJECTOR) Drug Patent Profile

Which patents cover Dawnzera (autoinjector), and what generic alternatives are available?

Dawnzera (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has three hundred and sixteen patent family members in forty countries.

The generic ingredient in DAWNZERA (AUTOINJECTOR) is donidalorsen sodium. One supplier is listed for this compound. Additional details are available on the donidalorsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Dawnzera (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DAWNZERA (AUTOINJECTOR)

International Patents:	316
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	DAWNZERA (AUTOINJECTOR) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DAWNZERA (AUTOINJECTOR)

NDA:

219407

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for DAWNZERA (AUTOINJECTOR)

DAWNZERA (AUTOINJECTOR) is protected by five US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes			Y	Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes				Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes

International Patents for DAWNZERA (AUTOINJECTOR)

When does loss-of-exclusivity occur for DAWNZERA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DAWNZERA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015252917
Australia	2019284028
Brazil	112016022855

Supplementary Protection Certificates for DAWNZERA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
3524680	C20250028	Finland
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307

Last updated: June 26, 2026

DAWNZERA (autoinjector) market dynamics and financial trajectory: sales outlook, payer drivers, and exclusivity risk

DAWNZERA (autoinjector) is commercializing in an environment shaped by (1) payer preference for injectable convenience devices, (2) switch-and-stay formulary tactics around site-of-therapy and adherence, and (3) tightening biosimilar or generic price pressure in adjacent injectable classes. A financial trajectory that starts with premium net pricing typically compresses as device-units scale, competitors widen contracting, and pharmacy benefit (PBM) coverage normalizes. The key near-term swing factors are reimbursement category design, patient-education support cost-per-start, and the timing of any exclusivity or patent challenges affecting the underlying molecule or device/platform.

The rest of the analysis is not possible to complete accurately because DAWNZERA (autoinjector) lacks sufficient identifying information in the provided prompt to map the product to an FDA label, active ingredient, NDA/BLA, launch date, dosing, target indication, and the legally relevant exclusivity or patent estate needed for a true market and financial trajectory assessment.

What is DAWNZERA (autoinjector) and what market segment does it compete in?

DAWNZERA is a branded autoinjector product, but the active ingredient and FDA-approved indication are not stated in the prompt. Without the molecule and label, it is not possible to determine whether the competitive set is dominated by biologics, small-molecule injectables, insulin-adjacent therapies, GLP-1 RA class drugs, migraine CGRP injectables, multiple sclerosis agents, RA biologics, oncology supportive injectables, or other categories that have distinct reimbursement and pricing mechanics.

Which payer channels are most likely to drive DAWNZERA uptake?

Autoinjectors typically win through:

• Higher adherence versus manual injection, improving persistence metrics tracked by payers
• Lower patient training burden versus syringe workflows
• Reduced infusion-center utilization if the label shifts therapy from clinic to home

But payer channel impact depends on whether DAWNZERA is a specialty pharmacy product, Medicare Part D, PBM-managed commercial formulary, or a pharmacy carve-out tied to specialty distribution and manufacturer-administered patient support.

How does DAWNZERA pricing typically evolve for autoinjector launches?

A standard autoinjector financial path for specialty injectables is:

• Launch-year net price held closer to WAC via manufacturer contracting and intolerance to prior-authorization delays
• Unit ramp aided by starter programs, bridge coverage, and prior authorization readiness
• Mid-term price compression as formulary position becomes contestable and competitors add device-enabled offerings

For DAWNZERA specifically, a quantified pricing trajectory requires:

• WAC and net price history
• Contracting terms (rebate and access)
• Channel mix (commercial versus Medicare versus Medicaid)
• Manufacturer payment obligations tied to patient support

None of those facts can be derived from the prompt alone.

What reimbursement and formulary tactics determine DAWNZERA market share?

Autoinjector uptake is shaped by:

• Step therapy design tied to earlier oral or less costly injectables
• Prior authorization criteria based on documentation of diagnosis and prior failures
• Quantity limits that affect both persistence and switching
• Manufacturer access support and nurse educator staffing requirements

The financial trajectory for a device product hinges on the “time-to-first-fill” and “time-to-authorization” cycle. That requires data that cannot be mapped without DAWNZERA’s active ingredient and indication.

When does DAWNZERA lose exclusivity, and what does that do to revenues?

Exclusivity loss can happen through one or more mechanisms:

• Patent expiration of composition-of-matter or method-of-use claims
• Formulation and device-related patent expiration
• Regulatory exclusivity (data exclusivity and clinical/biosimilar exclusivity where applicable)
• Orange Book listing removal or expiration triggering ANDA timelines

A precise exclusivity timeline requires the NDA/BLA number and the Orange Book patent list for DAWNZERA’s active ingredient. That linkage is not possible from the prompt.

What patents protect DAWNZERA autoinjector products, and how strong is the estate?

Patent strength assessment depends on:

• Number and type of patents in Orange Book (or BLA reference lists)
• Remaining claim term for each relevant jurisdiction
• Whether patents are device claims, formulation claims, or use claims
• Litigation posture and claim construction history

No patent identifiers, assignees, or jurisdictions are provided.

How do generics or biosimilars threaten DAWNZERA and when could entry occur?

Threat timing depends on:

• Whether DAWNZERA’s active ingredient is small molecule versus biologic
• Whether there are relevant unexpired exclusivities preventing abbreviated pathways
• Whether any paragraph IV ANDA or biosimilar litigation has been filed
• Settlement agreements restricting launch dates

A generics/biosimilars risk map cannot be produced without the active ingredient and regulatory classification.

What FDA status does DAWNZERA have, and what regulatory milestones matter to forecasting?

Forecasting needs:

• Approval date and label expansion history
• Supplement type (sBLA/sNDA or CBE supplements for devices and formulations)
• Postmarketing commitments that can affect supply continuity
• Any REMS, distribution, or safety-related limitations

None of these facts are included in the prompt.

How does DAWNZERA compare with competing autoinjector drugs on price, access, and uptake?

A competitive comparison requires:

• Therapeutic class and route comparison (autoinjector versus prefilled syringe versus pen)
• Payer positioning and step therapy sequencing
• Evidence of persistence and adherence advantages in real-world settings

Without the indication, the competitor set cannot be established.

Which companies typically compete for formulary coverage in autoinjector segments?

Competitors vary sharply by therapeutic area:

• In autoimmune biologics, biosimilar pressure and tender contracting dominate
• In endocrinology and cardiometabolic drugs, contracting with outcomes-based rebates and step therapy is common
• In oncology supportive care, hospital systems and specialty distribution shape share

The drug is not identified beyond “DAWNZERA (autoinjector).”

What litigation and Paragraph IV activity affects DAWNZERA revenue risk?

Paragraph IV filings and biosimilar litigation drive launch risk and royalty exposure. A credible revenue-risk model needs:

• Filed suit dates
• Stated patents in the Orange Book
• Court outcomes or settlement terms
• Triggered launch windows based on 180-day exclusivity or settlement design

No litigation docket information is provided.

What manufacturing or device-related IP barriers affect DAWNZERA commercialization?

Autoinjector products face device and manufacturing constraints that can impact:

• Supply ramp timing (lead times for device components and filling)
• Cost of goods and premium margins versus device platform partners
• Regulatory comparability if device changes are made during lifecycle

These must be anchored to the actual device technology and any publicly disclosed manufacturing or regulatory events, none of which are present in the prompt.

What financial metrics would best track DAWNZERA’s trajectory?

For an autoinjector drug, the standard KPI set is:

• Net sales and unit sales by quarter
• Channel mix and pharmacy specialty distribution share
• Gross-to-net including rebates and chargebacks
• Gross margin after device and manufacturing costs
• Patient starts, persistence, and switching metrics (managed by patient support teams)
• Cash impacts tied to milestones or royalties (if applicable)

No DAWNZERA issuer, parent company, or financial reporting line item is provided.

Key Takeaways

• DAWNZERA market dynamics are likely driven by device-enabled adherence, payer access design, and contracting pressures that compress net pricing over time.
• Revenue trajectory for an autoinjector generally follows a launch ramp then mid-term price and access normalization as competitive alternatives establish formulary footholds.
• A quantified exclusivity, patent, litigation, and regulatory forecast cannot be produced because the prompt does not identify DAWNZERA’s active ingredient, indication, NDA/BLA, or Orange Book patent list.

FAQs

1. How do autoinjector products typically win formulary placement versus prefilled syringes?
2. What KPIs best predict mid-term net price compression for specialty injectable launches?
3. How does patient support and training infrastructure influence time-to-first-fill for autoinjectors?
4. What does exclusivity loss usually mean for biosimilar or generic entry timelines in injectable classes?
5. How do manufacturing device-component supply constraints affect quarterly revenue ramp for autoinjectors?

References

1. (No citable sources were used because DAWNZERA’s active ingredient, FDA status, and patent/regulatory identifiers are not provided in the prompt.)